Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The RA Body Connection

Terry Hartnett  |  Issue: August 2008  |  August 1, 2008

The hypotheses for this study are:

  1. Patients with RA will have a higher total fat mass and lower total lean mass, a higher regional mass (in abdominal visceral and thigh deposits), a higher leptin and resistin and lower adiponectin level even after adjustment for differences in levels of physical activity, and inflammatory markers; and
  2. Compared with patients with RA with a favorable body composition profile, patients with RA with adverse body composition profile will have a higher prevalence of subclinical atherosclerosis, lower physical function, more disability, and more articular damage.

Future Trials

If these hypotheses are proven, Dr. Bathon says the next step would be a clinical trial that addresses modification of body composition. The exact design for a future study will depend on the primary goal. If the goal is to reduce the risk of cardiovascular events, then modifying body composition to a more favorable phenotype through diet and exercise should be combined with aggressive control of other risk factors, such as a tight control of lipids, glucose, and blood pressure.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There is increasing evidence to suggest that cardiovascular risk in RA patients may also be lowered via tight control of RA disease activity. “These two approaches would have to be combined somehow and such an algorithm would be complex,” she says. “The results of the current study will inform the development of clinical strategies to prevent or reverse adverse body composition, and will set the stage for the conduct of clinical trials to investigate the efficacy of modifying body composition on morbidity and mortality in RA.”

Terry Hartnett is a medical journalist based in Pittsburgh.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Diagnostic CriteriaResearchRheumatoid Arthritis (RA)

Related Articles

    Rheumatology’s Architect

    March 1, 2008

    Help the REF lay foundations for our future

    A Look Back & A Look Ahead: ACR Research and Education Foundation Turns 25

    August 1, 2010

    The ACR Research and Education Foundation turns 25

    Productive Partnership

    August 1, 2009

    The ACR and the REF work closely to support the future of rheumatology

    Partners in Advancing Rheumatology

    August 8, 2012

    The REF is making great strides in advancing treatment and finding cures for rheumatic disease.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences